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Abstract 
Resveratrol is a polyphenol mainly found in grapes and red wine that has been 
reported as a caloric restriction (CR) mimetic through Sirtuin 1 (SIRT1) activation. 
Resveratrol increases metabolic rate, insulin sensitivity, mitochondrial biogenesis, 
physical endurance and reduces fat accumulation in mice. In addition, resveratrol may 
be a powerful agent to prevent age-associated neurodegeneration and to improve 
cognitive deficits in Alzheimer’s disease (AD). Moreover, several findings support that 
longevity in mice could be promoted by CR . 
In this work, we studied the role of dietary resveratrol in SAMP8 mice, a model of age 
related AD. Here we found that resveratrol supplementation increases mean life 
expectancy and maximal life span in SAMP8 and in its control-related strain SAMR1. In 
addition, we also examined the resveratrol-mediated neuroprotective effects in 
several specifically AD hallmarks. We found that not only activates AMPK pathways 
and prosurvival routes such as SIRT1 in vivo, but also reduces cognitive impairment 
and has a neuroprotective role decreasing amyloid burden and reducing tau 
hyperphosphorylation. 
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1. Introduction 
Resveratrol (trans-3,4',5-trihydroxystilbene), a naturally occurring polyphenol mainly 
found in grapes and red wine, has been reported as a caloric restriction (CR) mimetic 
with potential anti-aging and anti-diabetogenic properties. Resveratrol increases 
metabolic rate, insulin sensitivity, mitochondrial biogenesis, physical endurance and 
reduces fat accumulation in mice (Lagouge et al., 2006; Baur et al., 2006). However, 
the most accepted mechanistic hypothesis is that resveratrol effects, similar to CR, are 
driven through Sirtuin 1 (SIRT1) regulation. CR and resveratrol lead to increases in the 
cellular AMP/ATP ratio which results in activation of AMPK that initiates a signaling 
process that recruit mediators of oxidative metabolism and mitochondrial biogenesis 
including PGC1α, PPARδ and others. Of note, resveratrol also activates AMPK, which 
regulates insulin sensitivity and mitochondrial biogenesis (Um et al., 2010; Ruderman 
et al., 2010). 
Several findings support that longevity can be promoted by CR (Weindruch et al., 1988, 
Selman et al., 2008) jointly with its broad anti-aging activity (Park et al., 2009). 
Similarly, resveratrol treatment has a range of beneficial effects in mice but up to now 
has failed to increase the longevity of ad libitum-fed animals when started midlife either 
alone or in combination with other anti-aging strategies such as CR (Baur and Sinclair, 
2006; Pearson et al., 2008). In addition, dietary resveratrol mimics the effects of CR 
in insulin mediated glucose uptake in muscle in aged animals and gene 
expression profiling suggests that both CR and resveratrol may retard some 
aspects of aging through alterations in chromatin structure and transcription 
(Halagappa et al., 2007; Barger et al., 2008). 
Several in vitro and in vivo studies also support the hypothesis that resveratrol may be 
a powerful agent to prevent age-associated neurodegeneration (Vingtdeux et al., 
2008). In in vitro models, resveratrol markedly lowers the levels of secreted and 
intracellular amyloid-beta (Aβ) peptides (Marambaud et al., 2005). Similarly, a grape 
seed polyphenolic extract administered orally to Tg2576 mice, a murine model of AD 
(Hsiao et al., 1996) improves cognitive deficits and these effects correlate with 
reductions in the amounts of high molecular weight Aβ assemblies in the brain (Wang 
et al., 2008). Similar findings are observed in animals after moderate consumption of 
red wines (Wang et al., 2006; Ho et al., 2008). Recently it has been showed that 
resveratrol selectively remodels soluble oligomers, fibrillar intermediates, and amyloid 
fibrils into alternative aggregated species that are non-toxic (Ladiwala et al., 2010). 
These studies and other support the theory that resveratrol or polyphenol derivatives 
could be useful therapeutic agents for AD (Ono et al., 2008, JBC). Nevertheless, it is 
unknown whether resveratrol has similar effects in age-related models of AD such as 
the age-accelerated mouse (SAMP8), a rodent strain increasingly being recognized as 
a model of age-related AD (Takeda 2009; Pallàs et al., 2008). To this end, the SAMP8 
strain is characterized by deficits in learning and memory, emotional disorders 
(reduced anxiety-like behavior), impaired immune response, etc (Yagi 1988, Flood et 
al., 1998). More importantly, SAMP8 mice also show AD-related pathology such as 
increases in Aβ (del Valle et al., 2010) and other protein aggregates (Manich et al., 
2011), alterations in APP processing by secretases (Morley et al., 2000 and 2002), 
cerebral amyloid angiopathy (del Valle et al., 2011) and increases in tau 
hiperphosphorylation (Canudas et al., 2005). 
Therefore, in this work we sought to elucidate the role of dietary resveratrol in the 
SAMP8 mouse. To this end, previous results in SAMP8 demonstrated that low doses 
and short-term administration of pterostilbene (poliphenolic derivative of resveratrol) 
show positive effects on behavior, reductions in tau phosphorylation (Chang et al., 
2011) and regulation of cascades associated with PPAR alpha. Based on these 
encouraging findings we thus determined the effects of long-term administration of 
resveratrol on longevity and signaling cellular processes activated by this polyphenol, 
namely: the SIRT1 pathway and AMPK system. We also extended these studies by 
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examining the resveratrol-mediated neuroprotective mechanism in several specifically 
AD hallmarks present in SAMP8 as Aβ accumulation and tau phosphorylation. 
 
 
2. Methods 
 
2.1. Animals and resveratrol diet 
110 SAMP8 and SAMR1 animals were used for the survival study. The animals 
received a standard diet (2018 Teklad Global 18% Protein Rodent Maintenance Diet, 
Harlan) or the same diet supplemented with trans-resveratrol (1g/Kg) starting at two 
months of age resulting in four groups of 50 to 60 individuals: SAMR1 control, SAMR1 
resveratrol, SAMP8 control and SAMP8 resveratrol. For the neurodegeneration 
studies, two groups of 10-12 SAMP8 mice were fed with the standard diet or the 
resveratrol diet, starting the supplementation at two months and sacrificing the animals 
so as to obtain tissue samples at 9 months of age. All the animals had food and water 
ad libitum and were kept in standard conditions of temperature (22 ± 2°C) and 12:12-h 
light-dark cycles (300 lux/0 lux). Studies were performed in accordance with the 
institutional guidelines for the care and use of laboratory animals established by the 
Ethical Committee for Animal Experimentation at the University of Barcelona. 
 
2.2. Object Recognition Test 
9-months SAMP8 control (P8ctl) and SAMP8 resveratrol (P8rsv) animals were placed 
in a 90º two arm, 25 cm long 20 cm high 5 cm wide, black maze. The 20 cm high walls 
could be lifted off for easy cleaning. The light intensity in the middle of the field was 30 
lux. The objects to be discriminated were made of plastic (5.25 cm high, object A and 
4.75 cm high, object B). The first three days mice were individually habituated to 
apparatus for 10 min. The 4th day, the animals were submitted to a 10 min acquisition 
trial (first trial) during which they were placed in the maze in the presence of two 
identical novel objects (A+A or B+B) placed at the end of each arm. A 10 min retention 
trial (second trial) occurred 2 h later. During this second trial objects A and B were 
placed in the maze and the time that the animal explored the new object (tn) and the 
old object (to) were recorded. A discrimination index was defined as (tn-to)/(tn+to). In 
order to avoid object preference biases, objects A and B were counterbalanced so that 
half of the animals in each experimental group were first exposed to the object A and 
then to the object B whereas the other half saw first the object B and then the object A 
was presented. The maze as well as the objects were cleaned with ethanol 96º 
between different animals so as to eliminate olfactory cues. 
 
2.3. Brain processing 
One day after the object recognition test had been conducted, 9-month animals were 
intracardially perfused after being anaesthetized with 80 mg/Kg of sodium 
pentobarbital. Afterwards, brains were dissected and separated sagitally in two 
hemispheres, one for immunohistochemistry and the other for protein extraction. 
Immunohystochemistry brains were frozen by immersion in isopentane, chilled in dry 
ice and stored at -80 ºC until sectioning. Thereafter, frozen brains were embedded in 
OCT cryostat-embedding compound (Tissue-Tek, Torrance, CA), cut into 20-μm-thick 
sections on a cryostat (Leyca Microsystems, Germany) at -18ºC, and placed on slides. 
Slides containing brain sections were fixed with acetone for 10 min at 4º C, allowed to 
dry at room temperature and then frozen at -20ºC until further staining. The cortex and 
hippocampus of the other hemisphere were dissected and stored at -80ºC until protein 
extraction (see below). 
 
2.4. Immunohistochemistry 
Slides were allowed to defreeze at room temperature and then rehydrated with PBS for 
5 min. Then, brain sections were blocked and permeabilized with PBS containing 1% 
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bovine serum albumin (BSA, Sigma–Aldrich) and 0.1% Triton-X-100 (Sigma–Aldrich) 
for 20 min. After two 5-min washes in PBS, slides were incubated with the primary 
antibody for Aβ40, Aβ42, (see list of antibodies and dilutions below) overnight at 4ºC. 
They were then washed again and incubated for 1 h at room temperature in the dark 
with AlexaFluor secondary antibody (see below). After washing again, nuclear staining 
 
was performed by incubating slides in Hoechst (H-33258, Fluka, Madrid, Spain) at 2 
μg/ml in PBS for 10 min at room temperature in the dark. Finally, slides were washed, 
mounted using Prolong Gold (Invitrogen) anti-fade medium, allowed to dry overnight at 
room temperature and stored at 4ºC. Image acquisition was performed with a 
fluorescence laser microscope (BX41, Olympus, Germany). 
 
2.5. Protein extraction 
Cortex and hippocampus were micronized through freezing with liquid nitrogen and 
grinding with a mortar. For total protein extraction, lysis buffer (50mM Tris HCl, 150mM 
NaCl, 5mM EDTA, 1% Triton X-100, pH 7.4) containing complete, Mini, EDTA-free 
Protease Inhibitor Cocktail (Roche, Mannheim, Germany) and Phosphatase Inhibitor 
Cocktail 1 (Sigma-Aldrich, St. Louis, MO, USA) were added to micronized tissue and 
left on ice for 30 min. Then, samples were centrifuged at 10000 g for 10 min and 
supernatant with total protein content was collected. All the protein extraction steps 
were carried out at 4ºC. Protein concentration was determined by the Bradford protein 
assay. 
 
2.6. Western Blot 
For Western Blot analysis, 20 ug of protein were denatured at 95 ºC for 5 min in 
sample buffer (0.5 M Tris-HCl, pH 6.8, 10% glycerol, 2% sodium dodecyl sulphate 
(SDS), 5% β-mercaptoethanol, 0.05% bromophenol blue) and separated by SDSPAGE 
on 10% polyacrylamide gels and transferred to Immobilon polyvinylidene 
difluoride membranes (Millipore, Billerica, MA, USA). The membranes were incubated 
overnight at 4°C with the primary antibodies (see table 1) diluted with Tris-buffered 
saline containing 0.1% Tween 20 (TBS-T) and 5% bovine serum albumin (BSA). 
Membranes were then washed and incubated with secondary antibodies (see table 1) 
with TBS-T for 1 hour at room temperature. Protein bands were visualized using a 
chemiluminescence detection kit (Amersham Biosciences). Band intensities were 
quantified by densitometric analysis, and values were normalized to β-actin. 
 
2.7. List of antibodies 
See table 1 
 
2.8. Statistical analysis 
Results were subjected to statistical analysis using GraphPad Prism software. Kaplan- 
Meier survival curve comparison was performed using the Log-Rank (Mantel-Cox) test. 
The other data are presented as mean ± SEM and means were compared with 
twotailed, 
unpaired Student’s t-test or ANOVA following Tukey's Multiple Comparison Test 
when necessary. In the ORT one-sample t test was used to examine whether single 
columns were different from zero. Statistical significance was considered when P 
values were <0.05. 
 
 
3. Results 
 
3.1. Increase of life expectancy by resveratrol. 
The survival curves were plotted using the Kaplan Meier plot. A shift to the right for the 
resveratrol groups reveals an increased expectancy of life for animals that had been 
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eating the resveratrol diet. The comparison of the groups using the Mantel-Cox log 
rank test indicates that there is a significant difference between the survival curves of 
the control group vs. the resveratrol group not only in SAMP8 mice (Fig. 1A, P<0.0001 
among groups Mantel-Cox log-rank test) but also in SAMR1 animals (Fig. 1B, P<0.01 
among groups Mantel-Cox log-rank test). In addition, the median life expectancy of our 
control mice was of 10.4 months for SAMP8 mice, significantly lower than the 17,8 
months of SAMR1 mice (Fig. 1C), in accordance to previous studies (Takeda 2009). 
However the SAMP8 resveratrol group showed a life expectancy of approximately 14 
months, showing an increase in life expectancy of over a 33 % over the control SAMP8 
mice (Fig. 1C). Furthermore, SAMR1 mice fed with resveratrol also presented a 
median lifespan of 21,8 months showing an increase of a 22 % in comparison with 
control SAMR1 mice (Fig. 1C). 
 
3.2. Resveratrol decreases cognitive impairment in SAMP8. 
We investigated the effect of a 7-months resveratrol food supplementation in 9-
monthold 
SAMP8 mice. This is an age when several alterations such as amyloid deposition 
or cognitive impairment have been reported (Pallàs et al., 2008). We found that, in the 
ORT, control mice had an impaired memory as their DI was close and not different 
from zero (fig. 2, P=0.4665, one-sample t-test) revealing there was no preference for 
the novel object. On the other hand, resveratrol mice had a positive DI different from 
zero (fig. 2, P<0.05, one-sample t-test) revealing that their memory was not impaired 
as they showed higher preference for the novel object than the already presented one. 
Furthermore, comparison of the two groups revealed a protective effect of resveratrol in 
the memory of animals in comparison with age matched SAMP8 mice (Fig. 2). 
 
3.3. Resveratrol increases both SIRT1 and AMPK levels while decreases P53 
acetylation. 
Western blot analysis of cortex and hippocampus of the two groups revealed higher 
levels of SIRT1 (Fig. 3A, B) in the animals that had been eating a diet supplemented 
with resveratrol in comparison with animals with standard food (control group). In 
accordance with this observation, the substrate of SIRT1, p53 shows a decrease in its 
acetylation in these brain areas (Fig. 3C, D). In addition, higher levels of 
phosphorylated AMPK (p-AMPK) were found in the cortex of the resveratrol group (fig. 
3E) while no modifications were seen in the AMPK levels (Fig. 3G). However, while no 
increment of p-AMPK levels was found in the hippocampus of the resveratrol mice (Fig. 
3F) an increase in AMPK basal levels appeared in these animals in comparison with 
control SAMP8 mice (Fig. 3H). 
 
3.4. Resveratrol reduces amyloid deposition and favors the non-amyloidogenic 
pathway in the hippocampus of SAMP8 mice. 
Immunohystochemistry was performed to brain sections with specific antibodies 
directed against the Aβ42 and Aβ40 to asses if there were differences between the two 
groups. Visual analysis revealed amyloid clusters limited only to the hippocampal area 
as described before (del Valle et al., 2010). In Figure 4 it can be seen that almost no 
Aβ granules were present in the resveratrol group while several clusters of Aβ42 and 
Aβ40 granules appeared in the control group (Fig. 4). Furthermore, we quantified the 
amount of amyloid clusters that were present in the hippocampus of the two groups. 
We found that resveratrol decreased the amount of both Aβ42 and Aβ40 accumulations 
in SAMP8 animals in comparison with control SAMP8 mice (Fig. 4B, C). In addition, 
western blot analysis was performed so as to quantify the levels of two enzymes 
responsible the amyloidogenic/non-amyloidogenic processing of APP, the α- 
(ADAM10) and β- (BACE) secretases. We found that while no alterations were seen in 
the pro-amyloidogenic BACE enzyme (Fig. 5 A-B), an increase in the 
nonamyloidogenic 
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ADAM-10 enzyme was found both in the cortex (fig. 5C) and the 
hippocampus (fig. 5D) of the resveratrol group. 
 
3.5. Resveratrol lowers Tau hyperphosphorylation at serine 396 and has a 
differential effect on Kinases of the cortex and the hippocampus. 
The levels of phosphorylated tau (pTau) at Ser396 have been described as a reliable 
marker of the severity of AD (Hu et al., 2002). Thus, we evaluated the effect of 
resveratrol on Tau phosphorylation levels in cortex and hippocampus extracts by 
Western blot using a tau antibody that detects only the pTau at Ser396. As can be seen 
in the figure 6, not only the cortex but also the hippocampus of animals fed with 
resveratrol showed lower levels of pTau (Fig. 6 A-B). In addition, we investigated the 
levels of CDK5 and the ratio of its activator p25 with the precursor p35 as well as the 
phosphorylated levels of GSK3β, CDC2 and JNK. With regard to the cortex of 
resveratrol animals, a diminution in CDK5 protein levels (Fig. 6C) altogether with a 
decrease in the p25/p35 ratio (Fig. 6E), revealing inactivation of this kinase, In addition, 
an increase in the levels of phosphorylated GSK3β at Ser9 can also be seen (Fig. 7A), 
a fact that also correlates with the reduced pTau levels as this enzyme is deactivated 
when phosphorylated at this residue. However, no modifications can be detected on 
the levels of phosphorylated CDC2 (Fig. 7C) nor in the levels of phosphorylated JNK 
(Fig. 7E). Conversely, there are no changes in resveratrol-treated-SAMP8 
hippocampus in comparison with age-matched SAMP8 control mice in studied kinases 
(Fig. 6 D, F and 7 B, D, F), but it was observed a significant diminution in pTau at 
Ser396 (Fig. 6B). 
 
 
4. Discussion 
 
The results stated here have confirmed the positive effect of resveratrol on extending 
lifespan, memory and neurodegenerative markers in the SAMP8 mice. 
SIRT1 activation by resveratrol increases the lifespan of S. Cerevisiae (Howitz et al., 
2003), C. Elegans (Viswanathan et al., 2005), D. Melanogaster (Wood et al., 2004) and 
the short-lived seasonal fish Nothobranchius furzeri (Valenzano et al., 2006). Here we 
demonstrate for the first time that resveratrol can extend lifespan in mice. Resveratrol 
supplementation in the diet resulted in a significant increase in mean life expectancy 
and in maximal life span, both in SAMP8 and SAMR1. At present, resveratrol was 
reported to prevent early mortality in mice fed with a high-fat diet (Baur et al., 2006) but 
failed to provide significant effects on survival in old mice (Miller et al., 2011). In 
SAMP8 mice only a growth hormone releasing hormone antagonist has been shown to 
extend their median lifespan (Banks 2010) and this action was associated with 
decreased brain oxidative stress. Melatonin has also been reported to increase life 
span and longevity in SAMR1 and SAMP8 mice (Rodriguez et al., 2008). These 
authors conclude that the underlying effects of this indoleamine relay on mitochondrial 
physiology improvement, then involving a decrease of reactive oxygen species 
generation. As old rodents produce more reactive oxygen species than young ones 
and the rate of mitochondrial reactive oxygen species production is inversely 
proportional to species maximum life span, it would be reasonable to expect that an 
agent that lowered reactive oxygen species might extend lifespan (Sohal et al, 1989). 
Sirtuins are deacetylases that show anti-aging properties in several animal models and 
can protect from stress (Donmez et al., 2010). SIRT1 plays a role in regulating different 
cellular processes through deacetylation of important substrates such as p53, FOXO 
transcription factors, PGC-1α, NFκB and others, which are closely linked to some age 
related diseases (Saunders et al., 2010). It is well established that CR is able to extend 
lifespan with a result of SIRT1 activation (Cohen et al., 2004) and it has been 
postulated that resveratrol mimics the effect of CR. In this study we demonstrate an 
increase in SIRT1 levels in SAMP8 treated with resveratrol in the two brain areas 
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studied, that correlated with a diminution in acetylated forms of p53, one of the main 
substrates of the deacetylase. In addition, SIRT1 pathways are closely related with 
AMPK signaling as a sensor of energy availability. AMPK is activated by 
phosphorylation of Thr-172 by LKB1 complex in response to increase in the AMP/ATP 
ratio and by calmodulin-dependent protein kinase kinase-beta (CamKKβ) in response 
to elevated Ca2+ levels, which contributes to regulating Aβ generation. It was reported 
that activation of deacetylase and AMPK are linked through LKB, and when SIRT1 is 
activated, AMPK is phosphorylated and also activated. Moreover, it has been recently 
demonstrated that resveratrol effects on SIRT1 activation are mediated via the 
CamKKβ-AMPK pathway by inhibiting cAMP-specific phosphodiesterases (PDE) (Park 
et al., 2012). Our results showed that resveratrol activation of SIRT1 in SAMP8 mice 
correlated with changes in the levels or in the phosphorylation of AMPK, demonstrating 
again that resveratrol is able to modify the SIRT11 pathway. 
Furthermore, a link between SIRT1 activation, AMPK and AD is increasingly evident 
(Gan, 2007). Tau phosphorylation and β-amyloid production are sensitive to AMPK 
inhibition (Greco et al., 2011; Park et al., 2012) as well as SIRT1 activation can prevent 
several signs of neurodegeneration (Bayod et al., 2012), protects against axonal 
degeneration (Araki et al., 2004), reduces poly-glutamine toxicity (Parker et al., 2005) 
and diminishes microglia-mediated Aβ toxicity (Chen et al., 2005). Resveratrol has 
been reported to improve memory alterations as it preserved cognitive function in aging 
mice (Oomen et al., 2009) and in transgenic AD mice (Kim et al., 2007). SAMP8 mice 
begin to show memory impairments at 6 months of age and memory related deficits get 
worse at 9 months of age (del Valle et al., JAD in press), here we found that resveratrol 
was able to revert the memory impairment previously reported. 
Part of the beneficial effects described for SIRT1 on Aβ accumulation is the modulation 
of α-secretases. Transcription of ADAM10 is positively controlled by retinoic acid 
receptors (RAR), which are activated by their ligand retinoic acid or through 
deacetylation by SIRT1. Using SIRT1-transgenic and SIRT1-deficient mice, this protein 
was found to activate the RARb transcription factor, which in turn increased ADAM10 
expression (Lichtenthaler 2011). In addition, SIRT1 activation reduced amyloid 
pathology in a mouse model of AD and crossing SIRT1 knockout mice with these mice 
dramatically increased Aβ burden (Donmez et al., 2010). Moreover, decreased SIRT1 
expression has been found in patients with AD and this decrease correlates with tau 
and Aβ levels (Julien et al., 2009). Modulation of ADAM10 expression by SIRT1 was 
demonstrated previously (Gutiérrez-Cuesta et al., 2008; Donmez et al., 2010). To this 
end, in our experimental paradigm, we found that resveratrol reduces Aβ burden in 
treated SAMP8 brain concomitantly with increases in ADAM10 expression. This effect 
can be considered specific because no changes were observed in the expression of 
other secretases, such as BACE (Donmez et al., 2010). Thus, resveratrol, through 
SIRT1 activation, specifically induced the non-amiloidogenic processing of nonmutated 
APP, reducing the presence of previously described amyloid deposits (del 
Valle et al., 2010). 
On the other hand, tau hypephosphorylation, another hallmark of AD, is mediated by 
several kinases in brain. We and others have demonstrated the aberrant 
phosphorylation of tau in brain of SAMP8 that is accomplished by activation of several 
tau kinases such as CDK5, GSK3β or JNK (Canudas 2005; Chang et al., 2011). Our 
data shows that in cortex of SAMP8 mice a diminution in CDK5 and GSK3β activity, 
both main tau kinases in AD, is induced by resveratrol treatment; and the inhibition of 
these tau kinases prevented tau phosphorylation in Ser396. 
On the other hand, no evident changes in JNK were found. Conversely, with low doses 
and only 2 months of treatment with pterostilbene, a resveratrol derivative, an inhibition 
of JNK was observed in SAMP8 but no changes in tau hyperphosphorylation 
(measured through PHF antibody) were observed in cortex (Chang et al., 2011). All 
these discrepancies are probably due to the different resveratrol doses and also to the 
long term treatment by resveratrol that we applied in the present study. 
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With regard to the hippocampus, although resveratrol was able to prevent tau 
phosphorylation, we were unable to find changes in the studied kinases. It is plausible 
to hypothesize that although long-term treatment by resveratrol prevents tau 
hyperphosphorylation detectable by using specific phospho-antibodies, the inhibition of 
intermediate signals under these conditions is lost because of the chronicity of the 
treatment. On the other hand, oxidative stress is a well-established pathogenic factor in 
AD (Smith et al., 1995; Markesbery 1997; Perry et al., 1998) and the association of 
oxidative stress with tau abnormalities is well known. As such, the resveratrol-driven 
reductions on tau phosphorylation in hippocampus could be mediated by the wellknown 
antioxidant effects of this polyphenol rather than through its inhibitory effect on 
tau kinases. Therefore, our results allow us to conclude that resveratrol is able to inhibit 
tau phosphorylation both in cortex and hippocampus. 
Taken together, in this study we demonstrate that resveratrol not only increases life 
expectancy, favors AMPK pathways and prosurvival routes such as SIRT1 activation 
but also has a neuroprotective role, reducing cognitive impairment in AD and other 
neurodegenerative parameters as neuronal cell death, amyloid burden and Tau 
hyperphosphorylation. 
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FIGURES 
 
 
Figure 1: Kaplan Meier plot with data expressed as % of alive individuals (A, B) and 
median lifespan of the four groups studied (C). Mantel-Cox log rank test analysis 
reveals a shift to the right for the resveratrol group in SAMP8 (A, P<0.0001) and 
SAMR1 (B, P=0.0051). In the median life-span comparison (C), results are expressed 
as mean ± SEM; ANOVA followed by Tukey's post test, ***P<0.001 vs. SAMP8, 
###P<0.001 vs. SAMR1. 
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Figure 2: Discrimination index (DI) of both groups of SAMP8 animals. Only Rsv group 
values are positive and different from zero (* P<0.05). There is a higher DI of Rsv 
animals in comparison with control SAMP8 mice (# P<0.05 vs. SAMP8 mice). Bars 
represent mean ± SEM. 
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Figure 3: Levels of Sirtuin (A, B), its acetylated substrate p53 (C, D), p-AMPK (E,F) 
and AMPK (G, H). Bars represent mean ± SEM and values are adjusted to 100% for 
levels of control SAMP8 mice. Student’s paired t-test; *p<0.05; **p<0.01 vs. SAMP8. 
Cx: Cortex, Hp: Hippocampus. 
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Figure 4: Representative hippocampal images of SAMP8 and SAMP8 Rsv animals 
(A), arrows (Aβ42) and arrowheads (Aβ40) indicate some clusters of amyloid granules in 
both groups. Quantification of the amount of Aβ42 (B) and Aβ40 (C) clusters in the 
hippocampus of the two groups. Bars represent mean ± SEM, values in D-G are 
adjusted to 100% for levels of control SAMP8 mice. Student’s paired t-test; *p<0.05; 
vs. SAMP8. Cx: Cortex, Hp: Hippocampus. 
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Figure 5: Cortex and hippocampal levels of BACE (A, B) and ADAM-10 (C, D) of 
SAMP8 and SAMP8 Rsv animals. Bars represent mean ± SEM, values in A-D are 
adjusted to 100% for levels of control SAMP8 mice. Student’s paired t-test; *p<0.05; 
**p<0.01 vs. SAMP8. Cx: Cortex, Hp: Hippocampus. 
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Figure 6: Levels of phosphorylated tau (pTau) at Ser396 in cortex (A) and hippocampus 
(B) of SAMP8 and SAMP8 Rsv groups. Cortex and hippocampal levels of CDK5 (C, D), 
P25/P35 ratio (E, F). Bars represent mean ± SEM and values are adjusted to 100% for 
levels of control SAMP8 mice. Student’s paired t-test; *p<0.05; **p<0.01 vs. SAMP8. 
Cx: Cortex, Hp: Hippocampus. 
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Figure 7: Cortex and hippocampal levels of p-GSK3ß (phosphorylated in Ser9) (A, B). 
p-cdc2 (phosphorylated in Tyr15) (C, D) and JNK (phosphorylated in Thr183/Tyr185) (E, 
F). Bars represent mean ± SEM and values are adjusted to 100% for levels of control 
SAMP8 mice. Student’s paired t-test; *p<0.05 vs. SAMP8. Cx: Cortex, Hp: 
Hippocampus. 
